- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04645836
Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Islamabad, Pakistan, 46000
- Pakistan Institute of Medical Sciences Islamabad
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Men and women
- Newly bacteriologically confirmed TB case (less than a month since diagnosis). This restriction (not more than one-month treatment) does not refer to patients whose most recent treatment outcome was a failure and who were assigned to a new treatment regimen.
- Own a mobile phone which operates on a telecom provider supported by our SMS platform
- Know how to and are able to receive SMS messages or Phone Call (Caretaker want to participate in case original patient do not participate)
- An address or residence location that is readily accessible for visiting, and willingness to inform the study team of any change of address during the treatment and follow-up period.
- No plans to move out of the catchment areas of the participating TB program sites within 9 months of enrollment.
- Facilities must have at least one TB doctor and one TB nurse available within the facility.
- Willingness to comply with study procedures and provide written informed consent prior to study enrollment.
Exclusion Criteria:
- Diagnosis is extra-pulmonary TB
- Currently enrolled in a clinical trial that prohibits enrollment in another study. Patients are leaving the area within the next six months.
- Patients are known at the start of treatment to require the treatment longer than it is recommended TB Management Guidelines for the appropriate type of TB.
- Previous history of TB, multidrug-resistant (MDR) or extensively drug-resistant (XDR) TB.
- Very ill patient's cognitive or physical disability that prevents full participation in the study such as vision, hearing, physically challenged, inability to swallow medications and unconscious Unable to answer questions.
- Pregnant females (treatment of TB infection will be deferred)
- Patients who are receiving treatment from private clinics (Who are not registered in the government TB sectors and they seek are form private health care facilities.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Interventionsgruppe
Ny behandlingsmetode: Farmaceutisk pleje En nyere strategi er farmaceutisk pleje, hvor et hospital giver rettidig patientuddannelse, overvågning og håndtering af bivirkninger, identificering af andre lægemiddelrelaterede problemer og en evaluering af behandlingsoverholdelse af en klinisk farmaceut. Ved det første besøg giver den kliniske farmaceut et mobiltelefonnummer og opfordrer patienterne til at kontakte dem når som helst, hvis de har brug for konsultation om TB-behandlingen. Short Message Service og telefonopkald daglig brug af mobiltelefonen til en TB-behandling vil understøtte den farmaceutiske pleje. TB-patienter eller familiemedlemmer vil modtage telefonopkald hver aften (undtagen søndag) under hele den ambulante TB-behandlingsfase for at sikre, at patienten tager den medicin, som TB-lægen har ordineret og givet, og for at indsamle oplysninger om behandlingsadhærens og mulige bivirkninger. |
New management mode intervention: Pharmaceutical care
Andre navne:
|
|
Ingen indgriben: Ingen interventionsgruppe.
Behandlingsgruppen inkluderet i kontrolarmen vil modtage traditionel - klinisk direkte observeret terapi (DOT) som anbefalet af Verdenssundhedsorganisationen og rutinebehandlingsgruppen (6 måneders behandlingsregime); Rutinemæssig sundhedsundervisning leveret af sundhedspersonale.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
TB treatment success rates
Tidsramme: 6-9 Months
|
TB treatment success rates defined by the World Health Organization.
The investigators will compare clinically reported treatment outcomes between the intervention and control groups.
|
6-9 Months
|
|
Adherence to treatment among drug-sensitive tuberculosis patients self reported and clinical record will checked for the follow up visits and drug taken
Tidsramme: 6-9 Months
|
Adherence Assessed daily from date of randomization until the date of a documented treatment outcome, up to 24 months after study enrollment date.Counting the number of administered pills, adequate adherence is more than 80% of administered pills.The measure adherence in TB patients for these determinations, we will measure patients' adherence via combined adherence endpoint consisting of Morisky Medication Adherence Scale and pill count rate.
|
6-9 Months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Health related Quality of Life of TB patients
Tidsramme: 6-9 Months
|
At baseline and upon completion of the treatment.
To measure HRQoL (Health related Quality of Life) Revalidated data assortment tool European Quality of Life Scale EQ 5D 3L
|
6-9 Months
|
|
Lost To Follow
Tidsramme: 6-9 Months
|
Lost to follow up or Treatment defaulters patients will be recorded from TB registers upon completion of the treatment
|
6-9 Months
|
|
Patient satisfaction questionnaire
Tidsramme: 6-9 Months
|
At baseline and upon completion of the treatment.
Satisfaction with information can be assessed with the satisfaction with information about medicines scale along with the Beliefs about medicines questionnaire.
|
6-9 Months
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studiestol: Yu Fang, Phd, Health Science Center of Xi'an Jiaotong University
- Studieleder: Amjad Khan, Phd, Quaid i Azam University Islamabad
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- FUKhan
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med TB
-
Shanghai Jiatan Pharmatech Co., LtdRekruttering
-
University of OxfordAfsluttetTBDet Forenede Kongerige
-
University of OxfordAfsluttetTBDet Forenede Kongerige
-
University of BergenAfsluttetUdstrygningspositive TB-tilfældeEtiopien
-
University of OxfordMedical Research CouncilAfsluttet
-
University of OxfordAfsluttetTBDet Forenede Kongerige
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)RekrutteringTB - Tuberkulose | TB | TB infektionIndien
-
Tuberculosis Research Centre, IndiaInternational Union Against Tuberculosis and Lung Diseases; Sarvodaya Charitable... og andre samarbejdspartnereAktiv, ikke rekrutterendePræ-ekstensivt lægemiddelresistent lunge-TB | Behandling Intolerant multiresistent lunge-TB | Ikke-responsiv multiresistent lunge-TBIndien
-
Universidad Nacional de CaaguazuIkke rekrutterer endnuEpidemiologi | Tuberkulose (TB) | Fanger | TB infektionParaguay
-
Seoul National University HospitalAfsluttetTBKorea, Republikken
Kliniske forsøg med New management mode
-
Afeka, The Tel-Aviv Academic College of EngineeringHebrew University of JerusalemAfsluttet
-
LivaNovaAfsluttetHjertefejl | KardiomyopatiHolland, Frankrig, Spanien, Italien, Tyskland, Det Forenede Kongerige
-
University of AarhusAarhus University Hospital Skejby; Aalborg University HospitalTilmelding efter invitationADHD - Attention Deficit Disorder med hyperaktivitet | OpmærksomhedskoncentrationssværDanmark
-
Mayo ClinicTilmelding efter invitationIn utero-procedure, der påvirker foster eller nyfødteForenede Stater
-
Helen MinnisKing's College London; National Institute for Health Research, United Kingdom og andre samarbejdspartnereAfsluttetMentalt helbred | MishandlingDet Forenede Kongerige
-
Paolo CorradiniUniversity of MilanAfsluttetLymfom | Myelomatose | Myeloproliferativ sygdomItalien
-
Tufts UniversityGeorge Washington UniversityAktiv, ikke rekrutterende
-
Board of Trustees of Illinois State UniversityUniversity of Colorado, Denver; Abbott; University of North Carolina, Greensboro og andre samarbejdspartnereRekrutteringHjertefejl | Hjertesvigt med reduceret udstødningsfraktion | Hjertesvigt med bevaret ejektionsfraktionForenede Stater
-
Family Transitions: Programs that WorkAfsluttetSkilsmisseForenede Stater